"Patients with metabolic-associated steatohepatitis (MASH) also showed higher LDH levels. LDH levels were positively linked ...

Pathology Department ... In the other 40.7%, cardiac abnormalities were noted, which included: (1) cardiomyopathies (23%) such as idiopathic fibrosis, left ventricular hypertrophy, hypertrophic ...

1 Patients with simple steatosis have a relatively benign ‘liver’ prognosis with a 1–2% risk of developing clinical evidence of cirrhosis over 15–20 years. Patients with non-alcoholic steatohepatitis ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

A research team has identified the transcription factor Lhx2 (LIM homeobox protein 2) as a key regulator in hepatic stellate ...

However, in 13.4% of patients, liver histology was unchanged - one had mild steatosis and one had cirrhosis. In one patient (6.7%), progression from mild steatosis to pericellular fibrosis was ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

“These viruses can cause cell death, and chronic infections can lead to scarring, or fibrosis ... since heart disease is the leading health risk for people with fatty liver.

After 96 weeks, 39% of patients offered a 50-mg dose of efruxifermin showed a clinically meaningful reduction in liver fibrosis, or scarring, without other symptoms of MASH getting worse ...

Data from the UDCA group; the clofibrate group showed no significant changes (not shown) in liver function and histology. #, fibrosis was assessed by FibroTest, not by pathology.